89BIO INC (ETNB) Stock Fundamental Analysis
NASDAQ:ETNB - Nasdaq - US2825591033 - Common Stock - Currency: USD
We assign a fundamental rating of 2 out of 10 to ETNB. ETNB was compared to 559 industry peers in the Biotechnology industry. While ETNB seems to be doing ok healthwise, there are quite some concerns on its profitability. ETNB is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year ETNB has reported negative net income.
ETNB had a negative operating cash flow in the past year.
In the past 5 years ETNB always reported negative net income.
In the past 5 years ETNB always reported negative operating cash flow.
1.2 Ratios
ETNB's Return On Assets of -56.45% is in line compared to the rest of the industry. ETNB outperforms 44.90% of its industry peers.
The Return On Equity of ETNB (-63.86%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.45% | ||
| ROE | -63.86% | ||
| ROIC | N/A |
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ETNB does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for ETNB has been increased compared to 1 year ago.
ETNB has more shares outstanding than it did 5 years ago.
The debt/assets ratio for ETNB is higher compared to a year ago.
2.2 Solvency
ETNB has an Altman-Z score of 8.82. This indicates that ETNB is financially healthy and has little risk of bankruptcy at the moment.
ETNB's Altman-Z score of 8.82 is amongst the best of the industry. ETNB outperforms 84.97% of its industry peers.
A Debt/Equity ratio of 0.06 indicates that ETNB is not too dependend on debt financing.
ETNB's Debt to Equity ratio of 0.06 is on the low side compared to the rest of the industry. ETNB is outperformed by 62.97% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 8.82 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
ETNB has a Current Ratio of 18.03. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 18.03, ETNB belongs to the best of the industry, outperforming 91.59% of the companies in the same industry.
ETNB has a Quick Ratio of 18.03. This indicates that ETNB is financially healthy and has no problem in meeting its short term obligations.
ETNB's Quick ratio of 18.03 is amongst the best of the industry. ETNB outperforms 91.77% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 18.03 | ||
| Quick Ratio | 18.03 |
3. Growth
3.1 Past
ETNB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -68.16%.
EPS 1Y (TTM)-68.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
3.2 Future
ETNB is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.50% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y37.99%
EPS Next 2Y15.6%
EPS Next 3Y10.67%
EPS Next 5Y18.5%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ETNB. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ETNB. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y15.6%
EPS Next 3Y10.67%
5. Dividend
5.1 Amount
No dividends for ETNB!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
10.41
+0.79 (+8.21%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners107.54%
Inst Owner Change29.21%
Ins Owners0.64%
Ins Owner Change18.42%
Market Cap1.52B
Analysts84.71
Price Target30.04 (188.57%)
Short Float %10.67%
Short Ratio7.23
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-13.1%
Min EPS beat(2)-29.63%
Max EPS beat(2)3.43%
EPS beat(4)2
Avg EPS beat(4)-30.31%
Min EPS beat(4)-112.45%
Max EPS beat(4)17.4%
EPS beat(8)4
Avg EPS beat(8)-17.78%
EPS beat(12)6
Avg EPS beat(12)-8.07%
EPS beat(16)8
Avg EPS beat(16)-8.82%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.82%
PT rev (3m)-0.71%
EPS NQ rev (1m)6.58%
EPS NQ rev (3m)-3.7%
EPS NY rev (1m)0%
EPS NY rev (3m)19.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | N/A | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 2.51 | ||
| P/tB | 2.51 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.38
EYN/A
EPS(NY)-2.28
Fwd EYN/A
FCF(TTM)-2.74
FCFYN/A
OCF(TTM)-2.74
OCFYN/A
SpS0
BVpS4.15
TBVpS4.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -56.45% | ||
| ROE | -63.86% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-50.79%
ROA(5y)-46.26%
ROE(3y)-61.77%
ROE(5y)-56.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.06 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 18.03 | ||
| Quick Ratio | 18.03 | ||
| Altman-Z | 8.82 |
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)20.59%
Cap/Depr(5y)70.69%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-68.16%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%9.26%
EPS Next Y37.99%
EPS Next 2Y15.6%
EPS Next 3Y10.67%
EPS Next 5Y18.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-124.09%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year9.05%
EBIT Next 3Y-3.98%
EBIT Next 5YN/A
FCF growth 1Y-360.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-360.43%
OCF growth 3YN/A
OCF growth 5YN/A